PROGNYX

Home/The Watchtower/FDA accelerated approval

Editorial illustration for the Prognyx briefing on dostarlimab (Jemperli), PD-1 checkpoint inhibitor

Briefing · From the Watchtower

FDA accelerated approval: GSK's Jemperli, first immunotherapy for dMMR rectal cancer

Accelerated approval rests on the single-arm AZUR-1 trial, where 68% of evaluable patients reached a clinical complete response at 12 months by investigator read while the blinded primary endpoint sits at 47% and is still maturing [1][2].

By · Founder, Prognyx ● Sourced to primary records Oncology
In brief: On 19 October 2026 the FDA granted accelerated approval to GSK's dostarlimab (Jemperli) for adults with Stage II/III MSI-H or dMMR locally advanced rectal cancer, the first and only immunotherapy cleared in this setting and a route that skips the chemoradiation and surgery that define current care [1][2]. The approval rests on the single-arm AZUR-1 trial of 154 patients, where 68% of evaluable patients reached a clinical complete response at 12 months by investigator assessment, while the primary endpoint by independent central review stands at 47% and is still maturing [1][2].

On 19 October 2026 the FDA granted dostarlimab (Jemperli) accelerated approval for adults with Stage II or III locally advanced rectal cancer that is MSI-H or mismatch repair deficient, confirmed by an FDA-authorized test [1]. GSK calls it the first and only immunotherapy approved in this setting [2][4]. Today's standard is chemotherapy, radiation and surgery, which GSK's own filing ties to lasting bowel, urinary and sexual dysfunction, secondary cancers and infertility [2]. The biomarker appears in roughly 5 to 10% of rectal cancers [2].

Why it matters

The approval creates an immunotherapy-first, organ-sparing route for a population that until now faced a morbid sequence to reach cure. For the 5 to 10% of rectal cancer patients who are dMMR or MSI-H, a single-agent PD-1 antibody given over nine cycles is now a labeled option [1][2].

The two numbers that matter

GSK leads with investigator-assessed response: 68% of evaluable patients (98/144; 95% CI 60 to 76%) reached a clinical complete response at 12 months [2]. An exploratory read put 76% (110/144) with no evidence of cancer a year or more after treatment, combining those 68% who reached that response without surgery and 12 patients whose complete response was confirmed pathologically after surgery; no recurrences were reported among responders after median follow-up beyond two years [2].

The trial's primary endpoint tells a more cautious story. By blinded independent central review, 47% (54/116; 95% CI 37 to 56%) have reached the 12-month complete response, with 38 more patients still moving toward that mark who have already achieved a clinical complete response [2].

Safety was consistent with the class. Serious adverse reactions occurred in 20% of patients; the most common were fatigue (32%), rash (22%), diarrhoea (18%) and pruritus (17%); 3% discontinued permanently [2].

Who gained, and the catch

AnaptysBio holds a financial interest in Jemperli royalties via Tesaro. It reported $644 million in global Jemperli net sales for the first half of 2026 (up 34% year on year) and $331 million in the second quarter alone, and guides to more than $390 million in annual royalties as early as 2029 at GSK's stated peak monotherapy guidance above $2.7 billion [3]. The commercial case just strengthened. The ownership economics did not settle with it: AnaptysBio and GSK/Tesaro went to trial in Delaware Chancery Court on 14 to 17 July 2026, a post-trial hearing fell on 20 October 2026 (the day after approval), and judgment is expected in Q4 2026 or Q1 2027, with AnaptysBio seeking reversion of Jemperli rights [3].

What to watch

  • Full AZUR-1 interim data at the ESMO Congress in October 2026 [2].
  • The independent-review complete response rate as those 38 patients reach 12 months [2].
  • AZUR-4, testing dostarlimab plus chemotherapy in MMR-proficient/MSS resectable colon cancer, with primary completion in Q4 2026 [3].
  • A new Phase 3 trial, NCT07740720, testing whether dostarlimab beyond nine cycles lifts complete response rates in the same LARC population; not yet recruiting, started 17 September 2026, primary completion 12 December 2029 [5].
  • The Delaware judgment in Q4 2026 or Q1 2027, and AZUR-2 and JADE readouts in 2028 [3].

The now-what

For a GI oncology developer, the comparator in dMMR disease has moved. An organ-preservation endpoint built against chemoradiation now has to answer to a single-agent PD-1 carrying a 68% investigator complete response [2]. Diagnostics is the second-order winner: reflex dMMR/MSI-H testing at rectal cancer diagnosis becomes gating, since the label depends on an FDA-authorized test [1]. For business development, the real option value is the AnaptysBio ruling; a reversion would change who monetizes an asset guided above $2.7 billion [3].

What Prognyx could not verify

The updated label text for the rectal cancer indication was not in the public record Prognyx read as of this briefing, and the full AZUR-1 efficacy and safety tables from the FDA page were truncated in the available text.

Verdict: high relevance for dMMR GI programs and rectal cancer diagnostics; the window to reset endpoints and testing assumptions is now, with ESMO data in October 2026 and the AnaptysBio ruling by Q1 2027 as the next resolving events.

Questions this briefing answers

Does this approval mean rectal cancer patients can avoid surgery?

For the MSI-H/dMMR subset, roughly 5 to 10% of rectal cancers, dostarlimab is now a labeled immunotherapy-first option; in the single-arm AZUR-1 trial, 68% of evaluable patients reached a clinical complete response at 12 months without surgery by investigator assessment [1][2]. The blinded primary endpoint by independent central review is lower, at 47%, and is still maturing [2].

Why is it called accelerated approval and what comes next?

Accelerated approval, aided by a National Priority Voucher, let the FDA clear dostarlimab ahead of its February 2027 PDUFA date, based on clinical complete response rather than long-term survival [2][3]. Full AZUR-1 interim data are due at the ESMO Congress in October 2026, and the independent-review response rate will continue to mature as 38 more patients reach the 12-month mark [2].

Sources: every claim traces to the primary record

  1. FDA OCE, accelerated approval of dostarlimab for locally advanced rectal cancer
  2. GSK Form 6-K (SEC), 19 October 2026
  3. AnaptysBio Form 8-K exhibit (SEC)
  4. GSK press release, Jemperli approved in US for MSI-H/dMMR locally advanced rectal cancer
  5. ClinicalTrials.gov NCT07740720

How this briefing was produced: Drafted and audited by the Prognyx engine against the primary sources cited above, then published automatically for clearing the audit threshold set by Rali Filali. Below that threshold, a briefing is not published. The full method.

Want this on your pipeline?
Get a free sample competitive brief on one of your assets, sourced, sharp, no strings.
Request a sample brief → Or read how Prognyx runs continuous oncology competitive intelligence.

Prognyx briefings are built from public information and reflect Prognyx's analysis. They are not investment advice and do not promote any product or off-label use.